Latest research · Nov 17, 2026
BioMarin (BMRN): Two 2027 FDA Decisions Test Voxzogo as Its Achondroplasia Sales Peak
Can Voxzogo hold ~$1.06B of sales after the Yuviwel royalty ends in May 2030, and how much of BioMarin's $57.23 share price, 20% above our $45.54 DCF, rests on Voxzogo growing toward $1.9B?
Open the full note